Baker BROS. Advisors LP Buys New Shares in Dyne Therapeutics, Inc. $DYN

Baker BROS. Advisors LP bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 813,449 shares of the company’s stock, valued at approximately $15,911,000.

Several other institutional investors have also recently made changes to their positions in DYN. AQR Capital Management LLC acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after purchasing an additional 366,183 shares during the period. Caxton Associates LLP acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $157,000. Finally, Creative Planning raised its holdings in shares of Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Up 6.3%

DYN opened at $19.20 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The firm has a market capitalization of $3.17 billion, a PE ratio of -5.96 and a beta of 1.09. The company’s 50-day moving average is $18.27 and its 200 day moving average is $18.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the business posted ($1.05) earnings per share. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Brian S. Posner bought 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were bought at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the acquisition, the director directly owned 24,500 shares of the company’s stock, valued at approximately $415,030. The trade was a 8.89% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Douglas Kerr sold 1,564 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the completion of the sale, the insider owned 170,042 shares in the company, valued at $3,121,971.12. This represents a 0.91% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have acquired 9,000 shares of company stock worth $156,800 and have sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DYN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Morgan Stanley dropped their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.85.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.